HQL
Price:
$13.79
Market Cap:
$377.16M
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of b...[Read more]
Industry
Asset Management
IPO Date
1992-05-01
Stock Exchange
NYSE
Ticker
HQL
According to Tekla Life Sciences Investors’s latest financial reports and current stock price. The company's current PE Ratio is 10.29. This represents a change of 1.40% compared to the average of 0.68 of the last 4 quarters.
The mean historical PE Ratio of Tekla Life Sciences Investors over the last ten years is 7.48. The current 10.29 PE Ratio has changed 13.65% with respect to the historical average. Over the past ten years (40 quarters), HQL's PE Ratio was at its highest in in the June 2021 quarter at 8.02. The PE Ratio was at its lowest in in the March 2018 quarter at -10277.26.
Average
7.48
Median
7.26
Minimum
-4.97
Maximum
18.73
Discovering the peaks and valleys of Tekla Life Sciences Investors PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 137.72%
Maximum Annual PE Ratio = 18.73
Minimum Annual Increase = -545.70%
Minimum Annual PE Ratio = -4.97
Year | PE Ratio | Change |
---|---|---|
2023 | 14.95 | -545.70% |
2022 | -3.35 | -142.89% |
2021 | 7.82 | 129.52% |
2020 | 3.41 | -168.60% |
2019 | -4.97 | -131.22% |
2018 | 15.91 | 137.72% |
2017 | 6.69 | -64.28% |
2016 | 18.73 | 71.21% |
2015 | 10.94 | 132.55% |
2014 | 4.71 | 37.98% |
The current PE Ratio of Tekla Life Sciences Investors (HQL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.47
5-year avg
3.57
10-year avg
7.48
Tekla Life Sciences Investors’s PE Ratio is greater than Tekla World Healthcare Fund (9.23), greater than Tekla Healthcare Opportunities Fund (7.15), greater than Royce Value Trust Inc. (8.31), greater than John Hancock Financial Opportunities Fund (3.75), less than Tekla Healthcare Investors (14.69), greater than Flaherty & Crumrine Dynamic Preferred and Income Fund Inc. (5.76), less than Cohen & Steers Infrastructure Fund, Inc (19.81), greater than Eaton Vance Tax-Advantaged Global Dividend Income Fund (6.43), greater than BlackRock MuniYield Fund, Inc. (-93.16), greater than Eaton Vance Tax-Advantaged Dividend Income Fund (8.29), greater than Eaton Vance Tax-Managed Buy-Write Income Fund (7.43), greater than Nuveen California Select Tax-Free Income Portfolio (7.72), greater than Cohen & Steers REIT and Preferred Income Fund, Inc. (7.70), greater than XAI Octagon Floating Rate & Alternative Income Term Trust (4.66), greater than Nuveen Preferred and Income Term Fund (7.56), greater than First Trust Intermediate Duration Preferred & Income Fund (6.62), greater than Flaherty & Crumrine Preferred Securities Income Fund Inc. (4.94), greater than Eaton Vance Risk-Managed Diversified Equity Income Fund (5.61),
Company | PE Ratio | Market cap |
---|---|---|
9.23 | $449.14M | |
7.15 | $819.77M | |
8.31 | $1.90B | |
3.75 | $731.87M | |
14.69 | $860.27M | |
5.76 | $413.43M | |
19.81 | $2.48B | |
6.43 | $1.45B | |
-93.16 | $510.39M | |
8.29 | $1.89B | |
7.43 | $436.21M | |
7.72 | $84.62M | |
7.70 | $1.10B | |
4.66 | $406.35M | |
7.56 | $463.19M | |
6.62 | $1.14B | |
4.94 | $746.28M | |
5.61 | $607.29M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tekla Life Sciences Investors using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tekla Life Sciences Investors or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tekla Life Sciences Investors's PE Ratio?
How is the PE Ratio calculated for Tekla Life Sciences Investors (HQL)?
What is the highest PE Ratio for Tekla Life Sciences Investors (HQL)?
What is the 3-year average PE Ratio for Tekla Life Sciences Investors (HQL)?
What is the 5-year average PE Ratio for Tekla Life Sciences Investors (HQL)?
How does the current PE Ratio for Tekla Life Sciences Investors (HQL) compare to its historical average?